1xgi: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
Line 1: Line 1:
[[Image:1xgi.gif|left|200px]]
{{Seed}}
[[Image:1xgi.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1xgi|  PDB=1xgi  |  SCENE=  }}  
{{STRUCTURE_1xgi|  PDB=1xgi  |  SCENE=  }}  


'''AmpC beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)-thiophene-2-carboxylic acid'''
===AmpC beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)-thiophene-2-carboxylic acid===




==Overview==
<!--  
Bacterial expression of beta-lactamases is the most widespread resistance mechanism to beta-lactam antibiotics, such as penicillins and cephalosporins. There is a pressing need for novel, non-beta-lactam inhibitors of these enzymes. One previously discovered novel inhibitor of the beta-lactamase AmpC, compound 1, has several favorable properties: it is chemically dissimilar to beta-lactams and is a noncovalent, competitive inhibitor of the enzyme. However, at 26 microM its activity is modest. Using the X-ray structure of the AmpC/1 complex as a template, 14 analogues were designed and synthesized. The most active of these, compound 10, had a K(i) of 1 microM, 26-fold better than the lead. To understand the origins of this improved activity, the structures of AmpC in complex with compound 10 and an analogue, compound 11, were determined by X-ray crystallography to 1.97 and 1.96 A, respectively. Compound 10 was active in cell culture, reversing resistance to the third generation cephalosporin ceftazidime in bacterial pathogens expressing AmpC. In contrast to beta-lactam-based inhibitors clavulanate and cefoxitin, compound 10 did not up-regulate beta-lactamase expression in cell culture but simply inhibited the enzyme expressed by the resistant bacteria. Its escape from this resistance mechanism derives from its dissimilarity to beta-lactam antibiotics.
The line below this paragraph, {{ABSTRACT_PUBMED_15796528}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 15796528 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15796528}}


==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: Cephalosporinase]]
[[Category: Cephalosporinase]]
[[Category: Serine hydrolase]]
[[Category: Serine hydrolase]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 15:00:00 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 06:06:26 2008''

Revision as of 03:06, 28 July 2008

File:1xgi.png

Template:STRUCTURE 1xgi

AmpC beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)-thiophene-2-carboxylic acid

Template:ABSTRACT PUBMED 15796528

About this Structure

1XGI is a Single protein structure of sequence from Escherichia coli. Full crystallographic information is available from OCA.

Reference

Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture., Tondi D, Morandi F, Bonnet R, Costi MP, Shoichet BK, J Am Chem Soc. 2005 Apr 6;127(13):4632-9. PMID:15796528

Page seeded by OCA on Mon Jul 28 06:06:26 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=1xgi&oldid=684700"